올레마 파머슈티컬(OLMA)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $9.82 (-0.81%), 시가총액 $1.22B, 52주 범위 $4.01 ~ $35.83.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor…
올레마 파머슈티컬의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
올레마 파머슈티컬의 현재 주가는 $9.82 (-0.81%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
올레마 파머슈티컬의 시가총액은 약 $1.22B입니다.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.